1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Hualan Biological Engineering Inc. Class A

Hualan Biological Engineering Inc. Class A

SSZSE:002007
12.89
CNY
+0.08
(+0.62%)
0.42EPS
30.00P/E
22.26BMarket Cap
Oct 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.62
0.69
0.81
1.07
1.31
1.77
2.04
2.76
2.44
2.47
2.93
2.4
2.52
2.03
Basic EPS, GAAP
0.26
0.3
0.32
0.43
0.45
0.63
0.71
0.89
0.71
0.59
0.81
0.6
0.52
0.41
Free Cash Flow per Basic Share
0.15
0.2
0.18
0.06
0.04
0.61
0.6
0.39
0.34
0.31
0.32
0.44
0.37
- -
Dividend per Share
0.04
0.13
0.19
0.13
0.22
0.15
0.22
0.31
0.31
0.22
0.31
0.26
0.75
0.69
Book Value per Share
1.7
1.88
2.02
2.33
2.57
3.05
3.59
4.13
4.57
5.7
6.21
6.48
6.29
6.01
Tangible Book Value per Share
1.62
1.76
1.91
2.21
2.46
2.93
3.47
4.01
4.44
5.52
6.02
6.29
6.11
5.82
Basic Weighted Avg Shares
1,801
1,813
1,814
1,814
1,814
1,814
1,817
1,818
1,821
1,825
1,824
1,826
1,826
1,826
Sales/Revenue/Turnover
1,118
1,243
1,472
1,935
2,368
3,217
3,700
5,023
4,436
4,517
5,342
4,379
4,595
3,713
Operating Margin (%)
43.02
42.7
41.12
41.94
38.15
39.87
40.64
41.91
39.45
31.71
36.46
29.02
27
22.7
Depreciation Expense
102
113
117
144
146
139
161
182
196
273
260
261
276
- -
Net Income, GAAP
475
538
589
780
821
1,140
1,283
1,613
1,299
1,076
1,482
1,088
940
742
Effective Tax Rate (%)
15.24
14.21
15.96
14.69
12.97
12.97
14.37
14.12
13.87
12.66
15.21
13.68
14.77
15.02
Profit Margin (%)
42.53
43.3
40.03
40.33
34.66
35.42
34.69
32.11
29.28
23.83
27.74
24.84
20.47
19.98
Working Capital
2,022
2,373
2,513
2,967
3,292
4,062
4,990
5,595
4,636
5,929
6,745
7,256
7,064
7,234
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
190
309
9
9
8
8
Total Equity
3,311
3,636
3,884
4,435
4,842
5,773
6,884
8,100
9,064
12,210
13,421
13,847
13,391
12,703
Return on Invested Capital (%)
14.5
14.07
14.92
17.17
17.25
22.93
21.94
23.96
15.74
10.73
12.93
8.23
7.4
5.67
Return on Capital (%)
15.31
15.26
15.86
18.97
17.92
20.24
18.87
18.02
12.52
7.97
8.74
7.07
6.22
5.1
Return on Common Equity (%)
16.75
16.62
16.69
19.82
18.48
22.36
21.27
22.93
16.37
11.49
13.62
9.37
8.05
6.41

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
447
- -
390
LT Borrowings
- -
- -
- -
LT Finance Leases
8
8
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,827
1,827
1,826
Market Capitalization
27,649
26,772
22,255

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
8,859
8,703
8,964
Cash, Cash Equivalents & STI
3,398
3,582
3,233
Accounts Receivable, Net
1,799
1,875
1,519
Inventories
2,289
2,540
2,720
Total Current Liabilities
1,795
1,324
1,730
Payables & Accruals
- -
- -
- -
ST Debt
447
- -
390
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.59%
11.28%
-3.29%
Free Cash Flow
137.51%
0.9%
-15.33%
Net Income, GAAP
7.57%
-7.82%
-13.55%
Sales/Revenue/Turnover
13.58%
-0.94%
4.93%
Total Cash Common Dividend
27.96%
36.93%
191.02%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
787
865
1,838
889
4,379
2025
868
931
- -
1,216
4,595
2026
762
805
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.1
0.26
0.09
0.6
2025
0.17
0.11
- -
0.09
0.52
2026
0.13
0.08
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.25
- -
- -
0.26
2025
0.05
0.13
- -
0.56
0.75
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Bei Fan
Full Time Employees
4,117
Sector
Health technology
Industry
Biotechnology
Address
No. 1 Hualan Avenue A Xinxiang HN China 453003
IPO Date
Jun 25, 2004
Website
hualanbio.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Hualan Biological Engineering Inc. (002007.SZ) researches, develops, produces and commercializes blood products, vaccines, and genetic engineering products in China; its core blood products include human albumin, intravenous human immunoglobulin, human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, human coagulation factor VIII, lyophilized human thrombin for external use, freeze-dried human fibrin glue for surgery, and human fibrinogen; vaccines comprise influenza vaccine (split virion, inactivated, adult and children), quadrivalent influenza vaccine (split virion, inactivated, adult), group ACYW135 meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine, group A and group C meningococcal polysaccharide vaccine, freeze-dried human rabies vaccine, and adsorbed tetanus vaccine. The company operates primarily in the biopharmaceutical sector, targeting healthcare providers, hospitals and public health programs with plasma-derived biologics, viral and bacterial vaccines, and recombinant proteins; it maintains plasma collection stations, poultry breeding for R&D, and contract manufacturing organization services. Founded in 1992 and headquartered in Xinxiang City, Henan Province, China, Hualan Biological Engineering Inc. holds subsidiaries such as Hualan Biological Vaccine Inc. for vaccine production. Recent developments include investing CNY 200 million in July 2025 for a 40% stake in Hualan Genetic Engineering Co., Ltd. during a CNY 500 million equity funding round that increased the subsidiary's capital to CNY 700 million; over the past two years, the company acquired three biopharmaceutical firms for around CNY 1 billion to expand its portfolio and distribution, alongside a partnership with a leading European pharmaceutical company for new biologics development projected to add CNY 300 million in annual revenue.